XML 50 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of option activity under the Company's equity plans, including the Company's inducement awards, is as follows for the year ended December 31, 2021:
(number of shares in millions)Number
of
shares		Weighted
average
exercise
price		Weighted
average
remaining
contractual
life (years)
Options outstanding at beginning of period5.2 $23.24 
Options granted— — 
Less:
Options exercised(3.7)24.26 
Options canceled or expired(0.1)25.18 
Options outstanding at end of period1.4 20.36 3.08
Options exercisable at end of period1.0 23.07 2.09
Options vested and expected to vest1.4 20.36 3.08
Summary of Stock Options Outstanding
The following table summarizes information about stock options outstanding at December 31, 2021 (number of shares in millions):
Options outstanding
Range of
exercise
prices		Number outstanding at December 31,
2021		Weighted
average
remaining
contractual
life (years)		Weighted
average
exercise
price
$13.38
0.7 5.62$13.38 
$23.98
0.1 0.1823.98 
$27.07 - 36.55
0.6 0.7427.25 
1.4 3.08$20.38 
Schedule of Restricted Stock Units Activity
A summary of the RSU activity under the Company's equity plans, including the Company's inducement awards and RSU awards with performance metrics, is as follows for the year ended December 31, 2021:
2021
(number of shares in millions)Number
of
shares		Weighted
average
grant date
fair value
RSUs unvested and outstanding at beginning of period3.2 $20.56 
RSUs granted1.8 29.83 
Less:
RSUs vested(1.1)21.32 
RSUs canceled(0.8)24.48 
RSUs unvested and outstanding at end of period3.1 $24.96 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows:
Year Ended December 31,Six-month Transition Period Ended December 31,Years Ended June 30,
(in millions)2021202020202019
Cost of molecular diagnostic testing$1.5 $0.6 $1.2 $0.8 
Cost of pharmaceutical and clinical services0.1 0.1 0.3 0.2 
Research and development expense4.2 2.4 5.0 5.4 
Selling, general, and administrative expense30.5 11.8 18.7 27.1 
Total stock-based compensation expense$36.3 $14.9 $25.2 $33.5 
Schedule of Aggregate Intrinsic Value
The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:
(in millions)As of
December 31, 2021
Aggregate intrinsic value of options outstanding$10.2 
Aggregate intrinsic value of options fully vested4.6 
Aggregate intrinsic value of RSUs outstanding86.3 
Schedule of Intrinsic Value of Options Exercised
The total intrinsic value of options exercised was as follows:
Year Ended December 31,Six-month Transition Period Ended December 31,Years Ended June 30,
(in millions)2021202020202019
Total intrinsic value of options exercised$29.2 $0.5 $8.8 $0.4 
Schedule of Shares Purchased and Compensation Expenses for ESPP Shares purchased under and compensation expense associated with the 2012 Purchase Plan for the years reported are as follows:
Year Ended December 31,Six-month Transition Period Ended December 31,Years Ended June 30,
(in millions)2021202020202019
Shares purchased under the plans0.2 0.1 0.3 0.2 
Plan compensation expense$1.5 $0.6 $1.7 $1.0 
Schedule of Valuation Assumptions for ESPP
The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the following weighted-average assumptions:
Year Ended December 31,Six-month Transition Period Ended December 31,Years Ended June 30,
2021202020202019
Risk-free interest rate0.1%0.2%1.8%2.1%
Expected dividend yield—%—%—%—%
Expected life (in years)0.50.50.50.5
Expected volatility60%94%99%55%